David Dai Analyst PerformanceDirector, Senior Biotech Analyst at UBS GroupDavid Dai is a stock analyst at UBS Group focused in the medical sector, covering 19 publicly traded companies. Over the past year, David Dai has issued 38 stock ratings, including buy and hold recommendations. While full access to David Dai's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Dai's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings42 Last 6 YearsBuy Recommendations70.73% 29 Buy RatingsCompanies Covered19 Unique Companies Ratings Distribution41RatingsDistribution of strong buy, buy, hold, and sell ratings by David Dai.RatingPercentageCount Strong Buy0.0%0 ratings Buy70.7%29 ratings Hold29.3%12 ratings Sell0.0%0 ratingsOut of 41 total stock ratings issued by David Dai at UBS Group, the majority (70.7%) have been Buy recommendations, followed by 29.3% Hold.Best & Worst CallsBest Call000.0%CGEMMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BIDUApr 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ89.5% of companies on NASDAQ17 companiesNYSEAMERICAN5.3% of companies on NYSEAMERICAN1 companyNYSE5.3% of companies on NYSE1 companyDavid Dai, an analyst at UBS Group, currently covers 19 companies listed on NASDAQ, NYSEAMERICAN and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies78.9%Computer and Technology3 companies15.8%Consumer Discretionary1 company5.3%David Dai of UBS Group specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology and Consumer Discretionary companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE13 companies68.4%SEQPT - WAFER FAB1 company5.3%ELEC COMP - SEMIC1 company5.3%SURGICAL & MEDICAL INSTRUMENTS1 company5.3%AUDIO/VIDEO PRD1 company5.3%MED - DRUGS1 company5.3%INTERNET SERVICES1 company5.3% About David DaiDavid Dai currently works at UBS Securities LLC, as Analyst from 2024. Mr. Dai also formerly worked at SMBC Nikko Securities America, Inc., as Vice President & Senior Biotech Analyst from 2021 to 2023, Jefferies LLC, as Associate from 2018 to 2019, and Barclays Capital, Inc., as Associate Vice President from 2019 to 2021. Mr. Dai received his undergraduate degree in 2006 from the University of British Columbia and Masters Business Admin degree in 2020 from The University of Chicago Booth School of Business.Follow on LinkedIn David Dai's Ratings History at UBS Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSNDXSyndax Pharmaceuticals6/12/2026Reiterated Rating$17.91Buy$0.0000.00% ROINUVLNuvalent6/10/2026Downgrade$123.25$124.00Neutral$0.0000.00% ROINUVLNuvalent6/10/2026Downgrade$123.25$124.00Neutral$0.0000.00% ROICLDXCelldex Therapeutics6/10/2026Boost Price Target$29.41$45.00Buy$0.0000.00% ROIBNTXBioNTech5/27/2026Upgrade$92.25$135.00Buy$0.0000.00% ROIASMLASML5/25/2026Reiterated Rating$1,632.90Buy$0.0000.00% ROIARMARM5/18/2026Initiated Coverage$209.16$300.00Outperform$0.0000.00% ROIARMARM5/18/2026Initiated Coverage$215.12$300.00Outperform$0.0000.00% ROISNDXSyndax Pharmaceuticals5/13/2026Lower Price Target$20.12$37.00Buy$0.0000.00% ROIASMLASML4/23/2026Reiterated Rating$1,454.97Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. JANXJanux Therapeutics4/15/2026Downgrade$15.24$15.00Neutral$0.0000.00% ROIASMLASML3/26/2026Boost Price Target$1,393.89$1,971.00Buy$0.0000.00% ROIJSPRJasper Therapeutics3/23/2026Initiated Coverage$1.23Neutral$0.0000.00% ROICATXPerspective Therapeutics3/18/2026Boost Price Target$4.95$8.00Buy$0.0000.00% ROISONYSony3/17/2026Reiterated Rating$21.67$22.00Market Perform$0.0000.00% ROISONYSony3/16/2026Downgrade$20.92$22.00Market Perform$0.0000.00% ROIKURAKura Oncology3/13/2026Reiterated Rating$8.61$15.00Buy$0.0000.00% ROIIOVAIovance Biotherapeutics3/5/2026Boost Price Target$4.16$4.00Neutral$0.0000.00% ROIKYMRKymera Therapeutics3/3/2026Boost Price Target$88.16$128.00Buy$0.0000.00% ROIASMLASML2/25/2026Reiterated Rating$1,497.80Buy$0.0000.00% ROIASMLASML1/29/2026Set Price Target$1,422.92$1,911.00$0.0000.00% ROIASMLASML1/22/2026Boost Price Target$1,360.09$1,642.00Outperform$0.0000.00% ROIASMLASML1/16/2026Reiterated Rating$1,358.57Buy$0.0000.00% ROISONYSony1/14/2026Reiterated Rating$24.41$30.00Outperform$0.0000.00% ROISONYSony1/14/2026Set Price Target$24.41$30.00Outperform$0.0000.00% ROIASMLASML1/5/2026Upgrade$1,163.78Buy$0.0000.00% ROIASMLASML1/4/2026Set Price Target$1,163.78$1,528.00Outperform$0.0000.00% ROINUVLNuvalent12/17/2025Reiterated Rating$102.44Buy$0.0000.00% ROIBNTXBioNTech12/4/2025Upgrade$97.28Hold$0.0000.00% ROIJANXJanux Therapeutics12/2/2025Reiterated Rating$17.97$57.00Buy$0.0000.00% ROIKURAKura Oncology11/14/2025Boost Price Target$12.35$16.00Buy$0.0000.00% ROIBNTXBioNTech11/6/2025Boost Price Target$103.43$117.00Neutral$0.0000.00% ROISNDXSyndax Pharmaceuticals11/4/2025Boost Price Target$14.98$38.00Buy$0.0000.00% ROINUVLNuvalent10/31/2025Boost Price Target$98.17$132.00Buy$0.0000.00% ROIMRUSMerus9/30/2025Downgrade$93.67$97.00Neutral$0.0000.00% ROISNDXSyndax Pharmaceuticals7/15/2025Lower Price Target$9.26$35.00Buy$0.0000.00% ROINRIXNurix Therapeutics7/10/2025Lower Price Target$12.67$26.00Buy$0.0000.00% ROISMMTSummit Therapeutics7/1/2025Initiated Coverage$21.28$30.00Buy$0.0000.00% ROIBPMCBlueprint Medicines6/5/2025Boost Price Target$128.10$129.00Neutral$0.0000.00% ROIIOVAIovance Biotherapeutics5/16/2025Downgrade$1.76$2.00Neutral$0.0000.00% ROIBefore you buy SpaceX shares, consider this alternative approach (Ad)SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.Discover the overlooked SpaceX IPO strategy before the June listingCGEMCullinan Therapeutics5/12/2025Lower Price Target$7.89$24.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenMorgan StanleyHSBCUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
